Do GLP-1 receptor agonists reduce cardiovascular events in type 2 diabetes?
In people with type 2 diabetes, GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE: cardiovascular death, non-fatal MI, non-fatal stroke). A meta-analysis of 8 cardiovascular outcome trials (>60,000 participants) found a 14% relative reduction in MACE, with consistent reductions in cardiovascular death, all-cause mortality, and a composite kidney outcome [1].
The benefit was broadly consistent across agents and was seen in patients with and without established cardiovascular disease, though absolute benefit is greatest in those with prior cardiovascular disease [1]. These findings underpin guideline recommendations to prefer agents with proven cardiovascular benefit in higher-risk patients.
The effect is a class-level signal driven largely by individual trials such as LEADER (liraglutide) and SUSTAIN-6 (semaglutide); not every agent has an individually significant MACE result, and gastrointestinal side effects are common [1].
- Trials enrolled predominantly high-cardiovascular-risk populations, so absolute benefit in low-risk primary prevention is less certain.
- Effect sizes differ by agent and formulation; the meta-analysis reports a pooled class effect, not equivalence between drugs.
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
Illustrative example of a CliniAtlas reading, for professional reference only. Verify as a healthcare professional to ask your own questions against live sources.